FluoGuide (FLUO) Stock Overview
A clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
FLUO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
FluoGuide A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 36.00 |
| 52 Week High | SEK 57.00 |
| 52 Week Low | SEK 29.10 |
| Beta | 0.76 |
| 1 Month Change | -7.93% |
| 3 Month Change | -20.00% |
| 1 Year Change | -30.77% |
| 3 Year Change | -32.84% |
| 5 Year Change | -70.73% |
| Change since IPO | 549.82% |
Recent News & Updates
Recent updates
Health Check: How Prudently Does FluoGuide (STO:FLUO) Use Debt?
Jul 26
Here's Why We're Watching FluoGuide's (STO:FLUO) Cash Burn Situation
Jan 22Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth
Jan 27FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans
Oct 07We're Hopeful That FluoGuide (STO:FLUO) Will Use Its Cash Wisely
May 21FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans
Jan 31Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth
Feb 25Shareholder Returns
| FLUO | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 2.0% | -1.0% | 0.6% |
| 1Y | -30.8% | -7.6% | 7.0% |
Return vs Industry: FLUO underperformed the Swedish Biotechs industry which returned -8.1% over the past year.
Return vs Market: FLUO underperformed the Swedish Market which returned 6.7% over the past year.
Price Volatility
| FLUO volatility | |
|---|---|
| FLUO Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 11.7% |
| 10% least volatile stocks in SE Market | 2.9% |
Stable Share Price: FLUO has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: FLUO's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 8 | Morten Albrechtsen | fluoguide.com |
FluoGuide A/S, a clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company has a collaboration agreement with ZEISS Medical Technologies for the development of FG001 for tumor imaging and surgical margins assessment for head and neck cancer.
FluoGuide A/S Fundamentals Summary
| FLUO fundamental statistics | |
|---|---|
| Market cap | SEK 588.58m |
| Earnings (TTM) | -SEK 50.56m |
| Revenue (TTM) | n/a |
Is FLUO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FLUO income statement (TTM) | |
|---|---|
| Revenue | -DKK 475.00k |
| Cost of Revenue | DKK 0 |
| Gross Profit | -DKK 475.00k |
| Other Expenses | DKK 34.64m |
| Earnings | -DKK 35.11m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 25, 2026
| Earnings per share (EPS) | -2.15 |
| Gross Margin | 100.00% |
| Net Profit Margin | 7,391.58% |
| Debt/Equity Ratio | -1,109.9% |
How did FLUO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/05 03:16 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
FluoGuide A/S is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christian Binder | Redeye |